Abstract
Omega-3 polyunsaturated fatty acids and antioxidants have important physiological functions in the brain including energy storage and production, gene expression, and cell signaling. Myelin is formed from the membranes of oligodendrocytes and phospholipid bilayers of these membranes which contain polyunsaturated fatty acids. Reactive oxygen species are created as part of the normal metabolism of oxygen within the cell and are important for cell signaling and homeostasis. Enzymes such as superoxide dismutase and glutathione are antioxidants that protect against free radicals that can damage cellular structure. Further, although the use of polyunsaturated fatty acid and antioxidants as potential therapeutic agents to treat individuals with or at risk for psychosis has generated considerable enthusiasm given their relative safety, minimal side effects, and low cost, clinical studies have yielded inconsistent evidence regarding their efficacy. The use of magnetic resonance imaging techniques such as diffusion tensor imaging and proton magnetic resonance spectroscopy, however, could provide information regarding the mechanism(s) of action for these compounds. For example, several studies have demonstrated a consistent relationship between peripheral omega-3 polyunsaturated fatty acid levels and fractional anisotropy, a putative measure of white matter integrity obtained using diffusion tensor imaging. Magnetic resonance imaging studies may also provide information about whether there are subgroups of individuals with psychosis who may be responsive to intervention with omega-3 polyunsaturated fatty acids and/or antioxidants. This approach could hold promise for better understanding how these compounds affect brain structure and function to elucidate possible targets for treatment intervention that can benefit patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ahmad A, Momenan R, van Gelderen P, Moriguchi T, Greiner RS, Salem N Jr. Gray and white matter brain volume in aged rats raised on n-3 fatty acid deficient diets. Nutr Neurosci. 2004;7(1):13–20. https://doi.org/10.1080/1028415042000202009.
Almaas AN, Tamnes CK, Nakstad B, Henriksen C, Grydeland H, Walhovd KB, et al. Diffusion tensor imaging and behavior in premature infants at 8 years of age, a randomized controlled trial with long-chain polyunsaturated fatty acids. Early Hum Dev. 2016;95:41–6. https://doi.org/10.1016/j.earlhumdev.2016.01.021.
Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54. https://doi.org/10.1001/archgenpsychiatry.2009.192.
Amminger GP, Mechelli A, Rice S, Kim SW, Klier CM, McNamara RK, et al. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Transl Psychiatry. 2015a;5:e495. https://doi.org/10.1038/tp.2014.134.
Amminger GP, Schafer MR, Schlogelhofer M, Klier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015b;6:7934. https://doi.org/10.1038/ncomms8934.
Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry. 2003a;53(1):56–64.
Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003b;62(3):195–204.
Basselin M, Ramadan E, Rapoport SI. Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans. Brain Res Bull. 2012;87(2–3):154–71. https://doi.org/10.1016/j.brainresbull.2011.12.001.
Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr. 2004;23(4):281–302.
Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry. 2013;3:e335. https://doi.org/10.1038/tp.2013.110.
Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry. 2007;68(12):1867–75.
Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology. 2008;33(10):2467–73. https://doi.org/10.1038/sj.npp.1301628.
Berger ME, Smesny S, Kim SW, Davey CG, Rice S, Sarnyai Z, et al. Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study. Transl Psychiatry. 2017;7(8):e1220. https://doi.org/10.1038/tp.2017.190.
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361–8. https://doi.org/10.1016/j.biopsych.2008.03.004.
Betensky JD, Robinson DG, Gunduz-Bruce H, Sevy S, Lencz T, Kane JM, et al. Patterns of stress in schizophrenia. Psychiatry Res. 2008;160(1):38–46. https://doi.org/10.1016/j.psychres.2007.06.001.
Bos DJ, van Montfort SJT, Oranje B, Durston S, Smeets PAM. Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: what is the evidence? Eur Neuropsychopharmacol. 2016;26(3):546–61. https://doi.org/10.1016/j.euroneuro.2015.12.031.
Bošnjak D, Kekin I, Hew J, Kuzman MR. Early interventions for prodromal stage of psychosis. Cochrane Database Syst Rev. 2016;(6). https://doi.org/10.1002/14651858.CD012236.
Cadenhead K, Addington J, Cannon T, Cornblatt B, Mathalon D, McGlashan T, et al. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal Studies (Napls) Consortium. Schizophr Bull. 2017;43:S16.
Cannon TD, Yu C, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, et al. An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry. 2016;173(10):980–8. https://doi.org/10.1176/appi.ajp.2016.15070890.
Chen AT, Chibnall JT, Nasrallah HA. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: possible stage-specific effects. Ann Clin Psychiatry. 2015;27(4):289–96.
Cox IJ, Puri BK. In vivo MR spectroscopy in diagnosis and research of neuropsychiatric disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;70(4):357–60. https://doi.org/10.1016/j.plefa.2003.12.010.
Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Ronci M, et al. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci. 2014;6:220. https://doi.org/10.3389/fnagi.2014.00220.
Cutuli D, Pagani M, Caporali P, Galbusera A, Laricchiuta D, Foti F, et al. Effects of omega-3 fatty acid supplementation on cognitive functions and neural substrates: a voxel-based morphometry study in aged mice. Front Aging Neurosci. 2016;8:38. https://doi.org/10.3389/fnagi.2016.00038.
Dalli J, Colas RA, Serhan CN. Novel n-3 immunoresolvents: structures and actions. Sci Rep. 2013;3:1940. https://doi.org/10.1038/srep01940.
Dangi B, Obeng M, Nauroth JM, Teymourlouei M, Needham M, Raman K, et al. Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J Biol Chem. 2009;284(22):14744–59. https://doi.org/10.1074/jbc.M809014200.
das Neves Duarte JM, Kulak A, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry. 2012;71(11):1006–14. https://doi.org/10.1016/j.biopsych.2011.07.035.
DeMar JC Jr, Ma K, Bell JM, Rapoport SI. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J Neurochem. 2004;91(5):1125–37. https://doi.org/10.1111/j.1471-4159.2004.02789.x.
Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002;159(9):1596–8. https://doi.org/10.1176/appi.ajp.159.9.1596.
Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res. 2006;84(1):112–20. https://doi.org/10.1016/j.schres.2006.03.023.
Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014;158(1–3):230–5. https://doi.org/10.1016/j.schres.2014.06.004.
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158(12):2071–4. https://doi.org/10.1176/appi.ajp.158.12.2071.
Gao H, Liu C, Song S, Zhang C, Ma Q, Li X, et al. GPX1 Pro198Leu polymorphism and GSTP1 Ile105Val polymorphisms are not associated with the risk of schizophrenia in the Chinese Han population. Neuroreport. 2017;28(15):969–72. https://doi.org/10.1097/WNR.0000000000000870.
Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, et al. Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. Neuropsychopharmacology. 2018;43(8):1700–5. https://doi.org/10.1038/s41386-018-0061-5.
Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 1998;30(3):193–208. https://doi.org/10.1016/S0920-9964(97)00151-5.
Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry. 1991;30(8):795–805.
Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res. 1994;13(3):195–207.
Jamilian H, Solhi H, Jamilian M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob J Health Sci. 2014;6(7 Spec No):103–8. https://doi.org/10.5539/gjhs.v6n7p103.
Jung WH, Borgwardt S, Fusar-Poli P, Kwon JS. Gray matter volumetric abnormalities associated with the onset of psychosis. Front Psychiatry. 2012;3:101. https://doi.org/10.3389/fpsyt.2012.00101.
Karlsgodt KH. Diffusion imaging of white matter in schizophrenia: progress and future directions. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(3):209–17. https://doi.org/10.1016/j.bpsc.2015.12.001.
Kaur G, Guo XF, Sinclair AJ. Short update on docosapentaenoic acid: a bioactive long-chain n-3 fatty acid. Curr Opin Clin Nutr Metab Care. 2016;19(2):88–91. https://doi.org/10.1097/MCO.0000000000000252.
Keshavan MS, Stanley JA, Montrose DM, Minshew NJ, Pettegrew JW. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo 31P MRS study. Mol Psychiatry. 2003;8(3):316–23., , 251. https://doi.org/10.1038/sj.mp.4001325.
Kim SW, Schafer MR, Klier CM, Berk M, Rice S, Allott K, et al. Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. Schizophr Res. 2014;158(1–3):39–44. https://doi.org/10.1016/j.schres.2014.06.032.
Kubicki M, McCarley R, Westin CF, Park HJ, Maier S, Kikinis R, et al. A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res. 2007;41(1–2):15–30. https://doi.org/10.1016/j.jpsychires.2005.05.005.
Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, et al. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0104-7.
Langbein K, Hesse J, Gussew A, Milleit B, Lavoie S, Amminger GP, et al. Disturbed glutathione antioxidative defense is associated with structural brain changes in neuroleptic-naive first-episode psychosis patients. Prostaglandins Leukot Essent Fatty Acids. 2018;136:103–10. https://doi.org/10.1016/j.plefa.2017.10.005.
Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A. 1996;93(18):9782–7.
Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995;11(4):376–81. https://doi.org/10.1038/ng1295-376.
Li Q, Leung YO, Zhou I, Ho LC, Kong W, Basil P, et al. Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model. Transl Psychiatry. 2015;5:e641. https://doi.org/10.1038/tp.2015.126.
Lindquist DM, Asch RH, Schurdak JD, McNamara RK. Effects of dietary-induced alterations in rat brain docosahexaenoic acid accrual on phospholipid metabolism and mitochondrial bioenergetics: an in vivo(31)P MRS study. J Psychiatr Res. 2017;95:143–6. https://doi.org/10.1016/j.jpsychires.2017.08.014.
Liu JJ, Green P, John Mann J, Rapoport SI, Sublette ME. Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res. 2015;1597:220–46. https://doi.org/10.1016/j.brainres.2014.11.059.
Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology. 2013;64:550–65. https://doi.org/10.1016/j.neuropharm.2012.07.019.
Magalhaes PV, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:CD008919. https://doi.org/10.1002/14651858.CD008919.pub2.
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and in cohorts of first-episode outcome patients—a systematic review. Arch Gen Psychiatry. 2005;62(9):975–83. https://doi.org/10.1001/archpsyc.62.9.975.
Matsuzawa D, Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal. 2011;15(7):2057–65. https://doi.org/10.1089/ars.2010.3453.
McGorry PD, Nelson B, Markulev C, Yuen HP, Schafer MR, Mossaheb N, et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiat. 2017;74(1):19–27. https://doi.org/10.1001/jamapsychiatry.2016.2902.
McNamara RK. Deciphering the role of docosahexaenoic acid in brain maturation and pathology with magnetic resonance imaging. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):33–42. https://doi.org/10.1016/j.plefa.2012.03.011.
McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, et al. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr Res. 2007;91(1–3):37–50. https://doi.org/10.1016/j.schres.2006.11.027.
McNamara RK, Asch RH, Schurdak JD, Lindquist DM. Glutamate homeostasis in the adult rat prefrontal cortex is altered by cortical docosahexaenoic acid accrual during adolescence: an in vivo(1)H MRS study. Psychiatry Res Neuroimaging. 2017a;270:39–45. https://doi.org/10.1016/j.pscychresns.2017.10.003.
McNamara RK, Szeszko PR, Smesny S, Ikuta T, DeRosse P, Vaz FM, et al. Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence. Neuroscience. 2017b;343:423–33. https://doi.org/10.1016/j.neuroscience.2016.12.007.
McNamara RK, Asch RH, Lindquist DM, Krikorian R. Role of polyunsaturated fatty acids in human brain structure and function across the lifespan: an update on neuroimaging findings. Prostaglandins Leukot Essent Fatty Acids. 2018a;136:23–34. https://doi.org/10.1016/j.plefa.2017.05.001.
McNamara RK, Schurdak JD, Asch RH, Peters BD, Lindquist DM. Deficits in docosahexaenoic acid accrual during adolescence reduce rat forebrain white matter microstructural integrity: an in vivo diffusion tensor imaging study. Dev Neurosci. 2018b;40(1):84–92. https://doi.org/10.1159/000484554.
McNamara RK, Schurdak JD, Asch RH, Lindquist DM. Omega-3 fatty acid deficiency impairs frontostriatal recruitment following repeated amphetamine treatment in rats: a 7 Tesla in vivo phMRI study. Nutr Neurosci. 2019;22(8):587–95. https://doi.org/10.1080/1028415X.2017.1419550.
Mellor JE, Laugharne JD, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res. 1995;18(1):85–6.
Mossaheb N, Schafer MR, Schlogelhofer M, Klier CM, Smesny S, McGorry PD, et al. Predictors of longer-term outcome in the Vienna omega-3 high-risk study. Schizophr Res. 2018;193:168–72. https://doi.org/10.1016/j.schres.2017.08.010.
Narr KL, Bilder RM, Toga AW, Woods RP, Rex DE, Szeszko PR, et al. Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb Cortex. 2005a;15(6):708–19. https://doi.org/10.1093/cercor/bhh172.
Narr KL, Toga AW, Szeszko P, Thompson PM, Woods RP, Robinson D, et al. Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol Psychiatry. 2005b;58(1):32–40. https://doi.org/10.1016/j.biopsych.2005.03.043.
Ozgen H, Baron W, Hoekstra D, Kahya N. Oligodendroglial membrane dynamics in relation to myelin biogenesis. Cell Mol Life Sci. 2016;73(17):3291–310. https://doi.org/10.1007/s00018-016-2228-8.
Parnanzone S, Serrone D, Rossetti MC, D’Onofrio S, Splendiani A, Micelli V, et al. Alterations of cerebral white matter structure in psychosis and their clinical correlations: a systematic review of diffusion tensor imaging studies. Riv Psichiatr. 2017;52(2):49–66. https://doi.org/10.1708/2679.27441.
Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawelczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res. 2016;73:34–44. https://doi.org/10.1016/j.jpsychires.2015.11.013.
Pawelczyk T, Piatkowska-Janko E, Bogorodzki P, Gebski P, Grancow-Grabka M, Trafalska E, et al. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: a secondary outcome analysis of the OFFER randomized controlled study. Schizophr Res. 2018;195:168–75. https://doi.org/10.1016/j.schres.2017.10.013.
Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res. 1995;29(3):227–32.
Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001;49(3):243–51.
Peet M, Horrobin DF, E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36(1):7–18. https://doi.org/10.1016/S0022-3956(01)00048-6.
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, et al. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study. Prostag Leukotr Ess. 2009;81(1):61–3. https://doi.org/10.1016/j.plefa.2009.04.007.
Peters BD, Machielsen MWJ, Hoen WP, Caan MWA, Malhotra AK, Szeszko PR, et al. Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull. 2013;39(4):830–8. https://doi.org/10.1093/schbul/sbs089.
Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch Gen Psychiatry. 1998;55(2):188–9.
Puri BK, Treasaden IH. A human in vivo study of the extent to which 31-phosphorus neurospectroscopy phosphomonoesters index cerebral cell membrane phospholipid anabolism. Prostaglandins Leukot Essent Fatty Acids. 2009;81(5–6):307–8. https://doi.org/10.1016/j.plefa.2009.10.003.
Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatridge A, et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract. 2000;54(1):57–63.
Puri BK, Counsell SJ, Hamilton G. Brain cell membrane motion-restricted phospholipids: a cerebral 31-phosphorus magnetic resonance spectroscopy study of patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2008;79(6):233–5. https://doi.org/10.1016/j.plefa.2008.08.002.
Rapoport SI. Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):79–85. https://doi.org/10.1016/j.plefa.2012.05.003.
Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull. 2004;30(4):901–11.
Rice SM, Schafer MR, Klier C, Mossaheb N, Vijayakumar N, Amminger GP. Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Res. 2015;228(1):174–6. https://doi.org/10.1016/j.psychres.2015.04.036.
Robinson DG, Gallego JA, John M, Hanna LA, Zhang J, Birnbaum ML, et al. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophr Res. 2019;204:295–303.
Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci U S A. 1996;93(9):4471–3.
Sedlak TW, Nucifora LG, Koga M, Shaffer LS, Higgs C, Tanaka T, et al. Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study. Mol Neuropsychiatry. 2018;3(4):214–22. https://doi.org/10.1159/000487639.
Silva RV, Oliveira JT, Santos BLR, Dias FC, Martinez AMB, Lima CKF, et al. Long-chain omega-3 fatty acids supplementation accelerates nerve regeneration and prevents neuropathic pain behavior in mice. Front Pharmacol. 2017;8:723. https://doi.org/10.3389/fphar.2017.00723.
Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1493–9. https://doi.org/10.1016/j.pnpbp.2007.07.004.
Skulas-Ray AC, Flock MR, Richter CK, Harris WS, West SG, Kris-Etherton PM. Red blood cell docosapentaenoic acid (DPA n-3) is inversely associated with triglycerides and C-reactive protein (CRP) in healthy adults and dose-dependently increases following n-3 fatty acid supplementation. Nutrients. 2015;7(8):6390–404. https://doi.org/10.3390/nu7085291.
Smesny S, Milleit B, Schaefer MR, Hipler UC, Milleit C, Wiegand C, et al. Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. Prostag Leukotr Ess. 2015;101:15–21. https://doi.org/10.1016/j.plefa.2015.07.001.
Sota M, Allegri C, Cortesi M, Barale F, Politi P, Fusar-Poti P. Targeting the effects of omega-3 and omega-6 fatty acid supplementation on schizophrenic spectrum disorders: role of neuroimaging. Med Hypotheses. 2007;69(2):466–7. https://doi.org/10.1016/j.mehy.2006.12.034.
Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics. 2003;13(3):145–57. https://doi.org/10.1097/01.fpc.0000054067.64000.8f.
Szeszko PR, Goldberg E, Gunduz-Bruce H, Ashtari M, Robinson D, Malhotra AK, et al. Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry. 2003;160(12):2190–7. https://doi.org/10.1176/appi.ajp.160.12.2190.
Tam EWY, Chau V, Barkovich AJ, Ferriero DM, Miller SP, Rogers EE, et al. Early postnatal docosahexaenoic acid levels and improved preterm brain development. Pediatr Res. 2016;79(5):723–30. https://doi.org/10.1038/pr.2016.11.
Titova OE, Sjogren P, Brooks SJ, Kullberg J, Ax E, Kilander L, et al. Dietary intake of eicosapentaenoic and docosahexaenoic acids is linked to gray matter volume and cognitive function in elderly. Age (Dordr). 2013;35(4):1495–505. https://doi.org/10.1007/s11357-012-9453-3.
Umhau JC, Zhou WY, Carson RE, Rapoport SI, Polozova A, Demar J, et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res. 2009;50(7):1259–68. https://doi.org/10.1194/jlr.M800530-JLR200.
van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res. 2012;141(2–3):153–61. https://doi.org/10.1016/j.schres.2012.08.014.
Wang DF, Cao B, Xu MY, Liu YQ, Yan LL, Liu R, et al. Meta-analyses of manganese superoxide dismutase activity, gene Ala-9Val polymorphism, and the risk of schizophrenia. Medicine (Baltimore). 2015;94(36):e1507. https://doi.org/10.1097/MD.0000000000001507.
Wheeler AL, Voineskos AN. A review of structural neuroimaging in schizophrenia: from connectivity to connectomics. Front Hum Neurosci. 2014;8:653. https://doi.org/10.3389/fnhum.2014.00653.
Witte AV, Kerti L, Hermannstadter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex. 2014;24(11):3059–68. https://doi.org/10.1093/cercor/bht163.
Wood SJ, Cocchi L, Proffitt TM, McConchie M, Jackson GD, Takahashi T, et al. Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study. Psychiatry Res. 2010;182(2):180–2. https://doi.org/10.1016/j.pscychresns.2009.12.003.
Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res. 1994;13(3):217–26.
Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 2000;42(1):7–17.
Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci. 2000;18(4–5):383–99.
Yousef N, Pistorius EK, Michel KP. Comparative analysis of idiA and isiA transcription under iron starvation and oxidative stress in Synechococcus elongatus PCC 7942 wild-type and selected mutants. Arch Microbiol. 2003;180(6):471–83. https://doi.org/10.1007/s00203-003-0618-4.
Yung AR, Nelson B. Young people at ultra high risk for psychosis: research from the PACE clinic. Rev Bras Psiquiatr. 2011;33(Suppl 2):s143–60.
Zamroziewicz MK, Paul EJ, Zwilling CE, Barbey AK. Predictors of memory in healthy aging: polyunsaturated fatty acid balance and fornix white matter integrity. Aging Dis. 2017;8(4):372–83. https://doi.org/10.14336/AD.2017.0501.
Zimmer L, Vancassel S, Cantagrel S, Breton P, Delamanche S, Guilloteau D, et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr. 2002;75(4):662–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Clari, R., McNamara, R.K., Szeszko, P.R. (2020). Omega-3 Polyunsaturated Fatty Acids and Antioxidants for the Treatment of Schizophrenia: A Role for Magnetic Resonance Imaging. In: Kubicki, M., Shenton, M. (eds) Neuroimaging in Schizophrenia . Springer, Cham. https://doi.org/10.1007/978-3-030-35206-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-35206-6_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35205-9
Online ISBN: 978-3-030-35206-6
eBook Packages: MedicineMedicine (R0)